| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.9 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |